New molecules modulating bone metabolism - new perspectives in the treatment of osteoporosis

In this review the authors outline traditional antiresorptive pharmaceuticals, such as bisphosphonates, monoclonal antibodies against RANKL, SERMs, as well as a drug with an anabolic effect on the skeleton, parathormone. However, there is also a focus on non-traditional strategies used in therapy fo...

Full description

Saved in:
Bibliographic Details
Published inPhysiological research Vol. 66; no. Suppl 3; pp. S341 - S347
Main Authors Zofkova, I, Blahos, J
Format Journal Article
LanguageEnglish
Published Czech Republic Institute of Physiology 01.01.2017
Subjects
Animals
Antibodies, Monoclonal - administration & dosage
Bisphosphonates
Bone density
Bone Density - drug effects
Bone Density - physiology
Bone morphogenetic proteins
Bone Remodeling - drug effects
Bone Remodeling - physiology
Bone turnover
Bones
Diphosphonates - administration & dosage
Epigenetics
Humans
Mesenchyme
Metabolism
Metabolites
Mineralization
miRNA
Monoclonal antibodies
Osteoblastogenesis
Osteoclastogenesis
Osteogenesis - drug effects
Osteogenesis - physiology
Osteolysis
Osteoporosis
Osteoporosis - drug therapy
Osteoporosis - metabolism
Pharmaceuticals
Proteins
Rheumatoid arthritis
Selective estrogen receptor modulators
Skeleton
Stem cells
Sulfasalazine
TRANCE protein
Treatment Outcome
Vitamin D
Vitamin D - administration & dosage
Wnt protein
Online AccessGet full text

Cover

More Information
Summary:In this review the authors outline traditional antiresorptive pharmaceuticals, such as bisphosphonates, monoclonal antibodies against RANKL, SERMs, as well as a drug with an anabolic effect on the skeleton, parathormone. However, there is also a focus on non-traditional strategies used in therapy for osteolytic diseases. The newest antiosteoporotic pharmaceuticals increase osteoblast differentiation via BMP signaling (harmine), or stimulate osteogenic differentiation of mesenchymal stem cells through Wnt/beta-catenin (icarrin, isoflavonoid caviunin, or sulfasalazine). A certain promise in the treatment of osteoporosis is shown by molecules targeting non-coding microRNAs (which are critical for osteoclastogenesis) or those stimulating osteoblast activity via epigenetic mechanisms. Vitamin D metabolites have specific antiosteoporotic potencies, modulating the skeleton not only via mineralization, but markedly also through the direct effects on the bone microstructure.
ISSN:0862-8408
1802-9973
DOI:10.33549/physiolres.933720